Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (trading symbol: OCX) on May 14, 2019. The filing serves to announce the company's financial results for the three-month period ended March 31, 2019. The registrant is incorporated in California and its common stock is listed on the NYSE American.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were issued in a press release (Exhibit 99.1) but does not contain the data itself within the body of the 8-K.
Material Changes
No material changes versus the prior comparable period are detailed in this filing text. The document references the attached press release for the full announcement of results but does not summarize specific variances or trends.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer regarding forward-looking statements, noting that actual results may differ materially from anticipated results due to various factors. It directs investors to the "Risk Factors" section of the company's Form 10-K for additional details. The company disclaims any obligation to update these forward-looking statements except as required by law.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 14, 2019) for specific revenue, net loss, and cash position figures.
- Verify the company's cash runway and liquidity status as detailed in the referenced press release.
- Consult the most recent Form 10-K for a comprehensive list of risk factors affecting the business.
- Confirm the trading status of OCX on the NYSE American following the announcement.